^
    Back
    Association details:
    Biomarker:TK1 elevation
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:fulvestrant (Selective estrogen receptor degrader) +
    anastrozole (Aromatase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SABCS 2020
    Title:

    Evaluating serum thymidine kinase 1 in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG S0226 trial

    Published date:
    11/17/2020
    Excerpt:
    For high sTK1, OS was significantly better for those treated with A+F vs. A alone who did not have prior adjuvant tamoxifen [HR=0.58; 95% CI (0.38-0.87); P=0.0087; 46 vs. 21 months], whereas for low sTK1 there was no difference by therapy (p=0.44).